PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients. […]
|
||||
PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients. […] PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients. […] The U.S. Food & Drug Administration (FDA) has decided to fast track SELLAS™ Life Sciences’ new drug Galinpepimut-S to treat pleural mesothelioma […] The U.S. Food and Drug Administration (FDA) has approved the drug Keytruda for patients with head and neck squamous cell carcinoma (HNSCC). […] |